Hemispherx (HEB) Discloses Possible FDA Delay Due To Scheduling Changes
Tweet Send to a Friend
Hemispherx Biopharma, Inc. (NYSE: HEB) today announced that the FDA has advised the company that it may require ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


